Tillman Gerngross (Craig F. Walker/The Boston Globe via Getty Images)

Af­ter rais­ing more than $750M in quick Covid cash, Till­man Gern­gross is on his way out of trou­bled Ada­gio

The renowned an­ti­body ex­pert Till­man Gern­gross found­ed Ada­gio in the fran­tic ear­ly days of the pan­dem­ic with a mis­sion to come up with a ground­break­ing an­ti­body to fight Covid-19. The first $50 mil­lion was com­mit­ted with­in 24 hours of his first calls. His biotech went pub­lic last sum­mer at $17 a share — af­ter rais­ing $470 mil­lion from the VCs — in the mid­dle of a biotech boom and quick­ly more than tripled in val­ue, spik­ing in a sec­ond big wave as Omi­cron stoked fresh fears of a tsuna­mi of cas­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.